Abstract
Over the past three decades, great efforts have been made to seek cancer chemoprevention strategies. Although the precise mechanisms promoting breast cancer are not completely established, thanks to increasing knowledge of the long process from normal to cancer cell, we can intervene with lifestyle, natural compounds, or drugs so that such process can be blocked or reversed. Moreover, the success of several recent clinical trials in the preventive setting in selected high-risk populations suggests that chemoprevention is an effective strategy. Breast cancer chemoprevention has heavily focused on endocrine intervention, although the drugs active in the prevention of endocrine responsive lesions have no effect in reducing the risk of estrogen-negative breast cancer. Thus, new pathways, biomarkers, and agents are actively searched in this subgroup of cancers and have been recently put under investigation. Finally, we should consider the current limited uptake of breast cancer chemoprevention and understand the different reasons to find appropriate solutions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699–2702
O’Shaughnessy AJ, Kelloff GJ, Gordon GB et al (2002) Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314–346
Meyskens FL Jr, Curt GA, Brenner DE et al (2011) Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) 4:311–323
Cummings SR, Tice JA, Bauer S et al (2009) Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 101:384–398
Mavaddat N, Pharoah PD, Michailidou K et al (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107(5):djv036
Althuis MD, Fergenbaum JH, Garcia-Closas M et al (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomark Prev 13:1558–1568
Cuzick J, DeCensi A, Arun B et al (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12:496–503
Powles TJ, Ashley S, Tidy A et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290
Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst 97:1652–1662
Veronesi U, Maisonneuve P, Rotmensz N et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst 99:727–737
Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282
Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300
Wickerham DL et al (2015) Final updated results of the NRG oncology/NSABP protocol P-2: study of tamoxifen and raloxifene (STAR) in preventing breast cancer. ASCO annual meeting. J Clin Oncol 33(suppl; abstr 1500):1500
Cuzick J, Sestak I, Bonanni B (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381:1827–1834
Decensi A, Bonanni B, Guerrieri-Gonzaga A et al (1998) Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90:1461–1467
Decensi A, Robertson C, Guerrieri-Gonzaga A et al (2009) Randomized double-blind 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 27:3749–3756
Guerrieri-Gonzaga A, Lazzeroni M, Botteri E et al (2013) Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. Ann Oncol 24:1859–1866
Decensi A, Bonanni B, Maisonneuve P et al (2013) A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol 24:2753–2760
Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23:1636–1643
Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509–518
Goss PE, Ingle JN, Alés-MartÃnez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381–2391
Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383:1041–1048
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643
Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502
Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938–1948
Garattini E, Bolis M, Garattini SK et al (2014) Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev 40:739–749
Veronesi U, Mariani L, Decensi A et al (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17(1065):1071
Gandini S, Puntoni M, Heckman-Stoddard BM et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 7:867–885
DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451–1461
Sahra IB, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576–3586
Bonanni B, Puntoni M, Cazzaniga M et al (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30:2593–2600
Hadad IT, Jordan L et al (2011) Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783–794
Niraula S, Dowling RJ, Ennis M et al (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821–830
Cazzaniga M, DeCensi A, Pruneri G et al (2013) The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 109:2792–2797
A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer. http://clinicaltrials.gov/show/NCT01101438
Phase II randomized study of neoadjuvant metformin plus letrozole vs placebo plus letrozole for er-positive postmenopausal breast cancer. http://clinicaltrials.gov/ct2/show/NCT01589367?term=han+metformin+breast&rank=1
Phase II pre-surgical intervention study for evaluating the effect of metformin on breast cancer proliferation. http://clinicaltrials.gov/ct2/show/NCT00930579?term=hershman+metformin+breast&rank=1
Metformin hydrochloride in patients with atypical hyperplasia or in situ breast cancer to placebo in decreasing atypical cells in patients with atypical hyperplasia or in situ breast cancer. http://clinicaltrials.gov/ct2/show/record/NCT01905046?term=phase+III+metformin+breast&rank=2
Choi YK, Park KG (2013) Metabolic roles of AMPK and metformin in cancer cells. Mol Cells 36:279–287
Phoenix KN, Vumbaca F, Claffey KP (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113:101–111
Hadji P, Coleman RE, Wilson C (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann Oncol 27:379–390
Hall TJ, Schaueblin M (1994) A pharmacological assessment of the mammalian osteoclast vacuolar H + −ATPase. Bone Miner 27:159–166
Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577–3581
Chleboski RT, Chen Z, Cauley JA et al (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582–3590
Lu C, Speers C, Zhang Y et al (2003) 2003 effect of epidermalgrowth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95:1825–1833
Hartmnn JT, Haap M, Kopp HG et al (2009) Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects. Curr Drug Metab 10:470–481
Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543
Lin NU, Carey LA, Liu MC et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993–1999
Strecke TE, Shen Q, Y Z et al (2009) Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101:107–113
Chan A, Delaloge S, Holmes FA (2016) Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:367–377
Kushi H, Doyle C, McCullough M et al (2012) American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 62:30–67
Reddy OB, Bhoola KD (2003) Natural products for cancer prevention: a global perspective. Pharmacol Ther 99:1–13
Wald J, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. BMJ 326:1419
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
De Censi, A., Bonanni, B., Cazzaniga, M. (2017). Chemoprevention. In: Veronesi, U., Goldhirsch, A., Veronesi, P., Gentilini, O., Leonardi, M. (eds) Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-48848-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-48848-6_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-48846-2
Online ISBN: 978-3-319-48848-6
eBook Packages: MedicineMedicine (R0)